Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145996 | 0.80 | SMN1; SMN2 (0.51) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL30241252 | 0.75 | MAOB (0.54) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL28996736 | 0.75 | MAOB (0.54) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL259563 | 0.74 | HPGD (0.55) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL3267547 | 0.73 | MAOA (0.54) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL28880946 | 0.72 | SMN1; SMN2 (0.53) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL3692740 | 0.71 | HPGD (0.51) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL5960738 | 0.71 | ALDH1A1 (0.42) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| SCHEMBL29089267 | 0.71 | SMN1; SMN2 (0.51) | HPGDSMN1; SMN2TYRDAOAKR1B1 | |
| Thiourea SCHEMBL6715523 | 0.71 | SMN1; SMN2 (0.46) | HPGDSMN1; SMN2TYRDAOAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024011209-A2 | ENGINEERED LIQUID CRYSTAL SHUTTER AS A DYNAMIC LONG-PASS OPTICAL FILTER | Blaze Bioscience, Inc. (US) | 2024-01-11 | — | — | WO | claimed |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | claimed |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | claimed |
| US-20230149478-A1 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2023-05-18 | — | — | US | claimed |
| EP-4172600-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS NEAR-INFRARED LIGHT AND VISIBLE LIGHT IMAGING | Blaze Bioscience, Inc. (US) | 2023-05-03 | — | — | EP | claimed |
| CN-116034301-A | System and method for simultaneous near infrared and visible imaging | 光明之火生物科学公司 | 2023-04-28 | — | — | CN | claimed |
| EP-4125829-A2 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021263159-A1 | SYSTEMS AND METHODS FOR SIMULTANEOUS NEAR-INFRARED LIGHT AND VISIBLE LIGHT IMAGING | Blaze Bioscience, Inc. (US) | 2021-12-30 | — | — | WO | claimed |
| WO-2021195344-A2 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-30 | — | — | WO | claimed |
| WO-2021126341-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. (US) | 2021-06-24 | — | — | WO | claimed |
| WO-2002079387-A2 | MODULAR MOLECULAR CLASPS AND USES THEREOF | ENGENEOS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020142336-A1 | Methods for determining a nucleotide at a specific location within a nucleic acid molecule | GENOME THERAPEUTICS CORPORATION (US) | 2002-10-03 | — | — | US | claimed |
| WO-2002063049-A2 | METHODS FOR DETERMINING A NUCLEOTIDE AT A SPECIFIC LOCATION WITHIN A NUCLEIC ACID MOLECULE | GENOME THERAPEUTICS CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1133697-B1 | METHOD FOR MODIFYING AND IDENTIFYING FUNCTIONAL SITES IN PROTEINS | XERION PHARMACEUTICALS GMBH (DE) | 2002-08-07 | — | — | EP | claimed |
| EP-1119315-A4 | DELIVERY OF PHOSPHOINOSITIDE POLYPHOSPHATES INTO CELLS | UNIV UTAH RES FOUND (US) | 2002-04-17 | — | — | EP | claimed |
| US-6320041-B1 | COMPOSITIONS COMPRISING ACTIVATED CARBOXYLIC ESTER MOIETY, ALKYL TETHER AND NUCLEIC ACID BINDING MOIETY | TRILINK BIOTECHNOLOGIES, INC. | 2001-11-20 | — | — | US | claimed |
| EP-1119315-A2 | DELIVERY OF PHOSPHOINOSITIDE POLYPHOSPHATES INTO CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2001-08-01 | — | — | EP | claimed |
| WO-2000018949-A9 | DELIVERY OF PHOSPHOINOSITIDE POLYPHOSPHATES INTO CELLS | UNIV UTAH RES FOUND (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000018949-A2 | DELIVERY OF PHOSPHOINOSITIDE POLYPHOSPHATES INTO CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-04-06 | — | — | WO | claimed |
| US-5453517-A | Covalently attached to fluorophores and/or polymers; detoxify excess metals, in vitro buffers, optical indicators of ionic transients | MOLECULAR PROBES, INC. (US) | 1995-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | HPGD 3614/4885SMN1; SMN2 4492/4885TYR 2506/4885 |
| US-20230149478-A1 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | SLC2A1, G6PD, HK1 | HPGD 586/4885SMN1; SMN2 1586/4885TYR 931/4885 |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | TYMP, DUT, NT5C3B | HPGD 432/4885SMN1; SMN2 2082/4885TYR 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.